



Cassiopea S.p.A.
Via Cristoforo Colombo, 1
20045 – Lainate (MI)

Object: Shareholders meeting on 29th April 2021 – List of board members of Cassiopea S.p.A.
proposed by Cosmo Pharmaceutical NV.

1st CANDIDATE

i.) Name: Pierpaolo Guzzo

ii.) Curriculum vitae:

- Italian (born 1968), in Rome, Italy.
- **2021 – today:** Board member and Executive Director, CFO of Cassiopea.
- **2015 – today:** Board member of Cassiopea.
- **2008 – today:** Founder and CEO of EQValue Partners, a consulting and investing company for SME's.
- **2000 – 2008:** Director at PM & Partners SpA a private equity fund focused on Italian companies.
- **1998 – 2000:** Investment manager at ABN AMRO Private Equity.
- **1996 – 1998:** Member of the M&A team of SOFIPA, an Italian merchant bank.
- **1993 – 1996:** Arthur Andersen working in the audit and the business consulting field.

2nd CANDIDATE.

i.) Name: Jan De Vries

ii.) Curriculum vitae:

- Dutch, (born 1944) resident in La Jolla (CA) USA;
- **2008 – today:** Board member of Cassiopea since 2015.
- **2020 – today:** CEO and co-founder of Tr1X bio Inc.

COSMO Pharmaceuticals N.V.

Registered Office:
Riverside II, Sir John Rogerson's Quay
Dublin 2, Ireland
Tel +353 (1) 8170370
info@cosmopharma.com
www.cosmopharma.com

Registered in Netherlands
Reg.Co. #65617738

Branch Registered in Ireland
Reg. Co. #908460
VAT #IE3419733KH

- **2017 – 2020:** Chairman of the board AIMM Therapeutics BV.
- **2012 – 2017:** CEO AIMM Therapeutics BV.
- **2010 – 2012:** Chairman of the board of Artax Inc.
- **2008 – 2010:** Head of Novartis Institutes for Biomedical Research, Europe.
- **1997 – 2008:** Global Head Autoimmunity, Transplantation and Inflammation, Novartis.
- **1989 – 1997:** Director of Human Immunology Department at DNAX Research Institute of Molecular and Cellular Biology (Schering Plough, now Merck).
- **1985 – 1989:** Co-director of the Schering Plough Laboratory for Immunological Research.
- **1978 – 1985:** Chairman of the Immunology Department at the Netherlands Cancer Institute which he joined in 1969.
- He brought 15 different compounds to advanced clinical trials, five of which (Elidel, Cosentyx, Gilenya, Ilaris and Maizent) are in the market.
- He has published more than 220 papers in scientific journals and written 80 book chapters and holds 20 patents. He received numerous awards and honors including the International Bekales Prize for Leukemia Research, the S. Johansson Lecture and Medal, the C. Praussnitz Prize and the Novartis innovation price.
- Dr de Vries has a PhD in immunology from the University of Amsterdam, a MSc degree in Biology/Biochemistry from the University of Utrecht and did postdoctoral studies at the University of California San Diego with Dr. John Mendelsohn.

3rd CANDIDATE.

i.) Name: Diana Harbort

ii.) Curriculum vitae:

- American, (born 1966) resident in Scottsdale (AZ) USA;
- **2015 – today:** Board member of Cassiopea;
- **2013 – 2015:** independent consultant;
- **2005 – 2012:** Head of Corporate Development at Medicis;
- **2003 – 2005:** Executive Director of Business Development at Medicis;
- **1998 – 2003:** Director Business Development at Medicis;
- **1989 – 1998:** she had various functions at Abbot Laboratories starting as a production planning specialist, then as a marketing product manager and finally as business development manager in the Chemical and Agricultural Products division.
- Diana Harbort has an MBA from Kellogg Graduate School of Management and a BBA of the University of Wisconsin.

4th CANDIDATE.

i.) Name: Øyvind Bjordal

ii.) Curriculum vitae:

- Norwegian, (born 1965) resident in Zumikon, Switzerland,
- **2015 – today:** Board member of Cassiopea.
- **2015 – today:** Managing Director and Head of Switzerland of Lincoln International, a corporate finance advisory company.
- **1999 – 2014:** Managing Director of a team of corporate financiers that initially worked at Arthur Anderson, E&Y, Sal Oppenheim and Leonardo &Co.

- **1994 – 1999:** Member of the Corporate Finance team at UBS and worked on transactions throughout Europe, including several privatisation assignments in the telecoms sector.

*** ** ***

Pursuant to the Articles of Association of Cassiopea S.p.A., it is hereby declared that at least one third of the candidates (namely: Øyvind Bjordal; Jan De Vries) fulfil the requirements of independence set forth at Section 2399, 1st Alinea, of the Italian Civil Code, and the requirements of independence provided by the Swiss Code of Best Practice for Corporate Governance.

Dublin, 19 April 2021

Cosmo Pharmaceuticals N.V.



Annexes:

- Declaration and acceptance by Pierpaolo Guzzo
- Declaration and acceptance by Jan De Vries
- Declaration and acceptance by Diana Harbort
- Declaration and acceptance by Øyvind Bjordal

Cassiopea S.p.A.
Via Cristoforo Colombo, 1
20045 – Lainate (MI)


Object: Shareholders meeting on 29th April 2021 – List of board members of Cassiopea S.p.A. proposed by Cosmo Pharmaceuticals N.V. – Declaration of acceptance of the candidature

I, the undersigned, accept the candidature on the List of board members of Cassiopea S.p.A. proposed by Cosmo Pharmaceuticals N.V. for the Shareholders meeting on 29th April 2021 and, also, I state, according to the section n. 13 of the Articles of Association, that:

- I. I fulfil the requirements of law and of the articles of association;
- II. there are neither conditions of ineligibility or incompatibility, nor potential conflicts of interest;
- III. I fulfil the independence requirements provided for section 2399, 1° alinea, of the Italian Civil Code, and the independence requirements provided by the Swiss Code of Best Practice for Corporate Governance;
- IV. I am a statutory auditor enrolled in the dedicated Italian register.

Acceptance:

Date: April 16th,2021

Name: Pierpaolo Guzzo, 

Annex: curriculum vitae

i.) Name: Pierpaolo Guzzo

ii.) Curriculum vitae:

- Italian (born 1968), in Rome, Italy;
- **2021 – today:** Board member and Executive Director, CFO of Cassiopea.
- **2015 – today:** Board member of Cassiopea.
- **2008 – today:** Founder and CEO of EQValue Partners, a consulting and investing company for SME's.
- **2000 – 2008:** Director at PM & Partners SpA a private equity fund focused on Italian companies,
- **1998 – 2000:** Investment manager at ABN AMRO Private Equity,
- **1996 – 1998:** Member of the M&A team of SOFIPA, an Italian merchant bank.
- **1993 – 1996:** Arthur Andersen working in the audit and the business consulting field.

Cassiopea S.p.A.
Via Cristoforo Colombo, 1
20045 – Lainate (MI)

Object: Shareholders meeting on 29th April 2021 – List of board members of Cassiopea S.p.A. proposed by Cosmo Pharmaceuticals N.V. – Declaration of acceptance of the candidature

I, the undersigned, accept the candidature on the List of board members of Cassiopea S.p.A. proposed by Cosmo Pharmaceuticals N.V. for the Shareholders meeting on 29th April 2021 and, also, I state, according to the section n. 13 of the Articles of Association, that:

- I. I fulfil the requirements of law and of the articles of association;
- II. there are neither conditions of ineligibility or incompatibility, nor potential conflicts of interest;
- III. I fulfil the independence requirements provided for section 2399, 1° alinea, of the Italian Civil Code, and the independence requirements provided by the Swiss Code of Best Practice for Corporate Governance.

Acceptance: 

Date: April 16th, 2021

Name: Jan De Vries, _____

Annex: curriculum vitae

i.) Name: Jan De Vries

ii.) Curriculum vitae:

- Dutch, (born 1944) resident in La Jolla (CA) USA;
- **2008 – today:** Board member of Cassiopea since 2015.
- **2020 – today:** CEO and co-founder of Tr1X bio Inc,
- **2017 – 2020:** Chairman of the board AIMM Therapeutics BV
- **2012 – 2017:** CEO AIMM Therapeutics BV,
- **2010 – 2012:** Chairman of the board of Artax Inc
- **2008 – 2010:** Head of Novartis Institutes for Biomedical Research, Europe.
- **1997 – 2008:** Global Head Autoimmunity, Transplantation and Inflammation, Novartis
- **1989 – 1997:** Director of Human Immunology Department at DNAX Research Institute of Molecular and Cellular Biology (Schering Plough, now Merck);
- **1985 – 1989:** Co-director of the Schering Plough Laboratory for Immunological Research;
- **1978 – 1985:** Chairman of the Immunology Department at the Netherlands Cancer Institute which he joined in 1969;
- He brought 15 different compounds to advanced clinical trials, five of which (Elidel, Cosentyx, Gilenya, Ilaris and Maizent) are in the market.
- He has published more than 220 papers in scientific journals and written 80 book chapters and holds 20 patents. He received numerous awards and honors including the International Bekales Prize for Leukemia Research, the S. Johansson Lecture and Medal, the C. Praussnitz Prize and the Novartis innovation price.
- Dr de Vries has a PhD in immunology from the University of Amsterdam, a MSc degree in Biology/Biochemistry from the University of Utrecht and did

postdoctoral studies at the University of California San Diego with Dr. John Mendelsohn.

Cassiopea S.p.A.
Via Cristoforo Colombo, 1
20045 – Lainate (MI)

Object: Shareholders meeting on 29th April 2021 – List of board members of Cassiopea S.p.A. proposed by Cosmo Pharmaceuticals N.V. – Declaration of acceptance of the candidature

I, the undersigned, accept the candidature on the List of board members of Cassiopea S.p.A. proposed by Cosmo Pharmaceuticals N.V. for the Shareholders meeting on 29th April 2021 and, also, I state, according to the section n. 13 of the Articles of Association, that:

- I. I fulfil the requirements of law and of the articles of association;
- II. there are neither conditions of ineligibility or incompatibility, nor potential conflicts of interest

Acceptance:

Date: April 16th, 2021

Name: Diana Harbort



Annex: curriculum vitae

Name: Diana Harbort

ii.) Curriculum vitae:

- American, (born 1966) resident in Scottsdale (AZ) USA;
- **2015 – today:** Board member of Cassiopea;
- **2013 – 2015:** independent consultant;
- **2005 – 2012:** Head of Corporate Development at Medicis;
- **2003 – 2005:** Executive Director of Business Development at Medicis;
- **1998 – 2003:** Director Business Development at Medicis;
- **1989 – 1998:** she had various functions at Abbot Laboratories starting as a production planning specialist, then as a marketing product manager and finally as business development manager in the Chemical and Agricultural Products division.
- Diana Harbort has an MBA from Kellogg Graduate School of Management and a BBA of the University of Wisconsin.

Cassiopea S.p.A.
Via Cristoforo Colombo, 1
20045 – Lainate (MI)

Object: Shareholders meeting on 29th April 2021 – List of board members of Cassiopea S.p.A. proposed by Cosmo Pharmaceuticals N.V. – Declaration of acceptance of the candidature

I, the undersigned, accept the candidature on the List of board members of Cassiopea S.p.A. proposed by Cosmo Pharmaceuticals N.V. for the Shareholders meeting on 29th April 2021 and, also, I state, according to the section n. 13 of the Articles of Association, that:

- I. I fulfil the requirements of law and of the articles of association;
- II. there are neither conditions of ineligibility or incompatibility, nor potential conflicts of interest;
- III. I fulfil the independence requirements provided for section 2399, 1° alinea, of the Italian Civil Code, and the independence requirements provided by the Swiss Code of Best Practice for Corporate Governance.

Acceptance:

Date: April 16th, 2021

Name: Øyvind Bjordal, _____



Annex: curricula vitae

i.) Name: Øyvind Bjordal

ii.) Curriculum vitae:

- Norwegian, (born 1965) resident in Zumikon, Switzerland,
- **2015 – today:** Board member of Cassiopea.
- **2014 – today:** Managing Director and Head of Switzerland of Lincoln International, a corporate finance advisory company.
- **1999 – 2013:** Managing Director of a team of corporate financiers that initially worked at Arthur Anderson, E&Y, Sal Oppenheim and Leonardo &Co.
- **1994 – 1999:** Member of the Corporate Finance team at UBS and worked on transactions throughout Europe, including several privatisation assignments in the telecoms sector.